#USA #New York #The Gross Law Firm #Stockholder Rights #Cytokinetics

Important Alert for Cytokinetics Investors

The investing community surrounding Cytokinetics, Incorporated (NASDAQ: CYTK) should take heed of a critical announcement made by The Gross Law Firm. Shareholders who acquired stocks in Cytokinetics during the designated class period are encouraged to reach out before November 17, 2025. This notice primarily serves to inform stockholders about the potential to engage in a class action lawsuit that seeks recovery for financial losses experienced during this timeframe.

Key Information for Shareholders

The class period specified for participation runs from December 27, 2023, to May 6, 2025. Allegations have surfaced indicating that Cytokinetics may have issued materially false and misleading statements about the timeline for its New Drug Application (NDA) for aficamten. The company reportedly claimed it was expecting approval from the U.S. Food and Drug Administration (FDA) in the latter half of 2025. This was based on information provided at a PDUFA (Prescription Drug User Fee Act) date marked for September 26, 2025.

The complaint details how Cytokinetics did not disclose significant risks tied to the omission of submitting a Risk Evaluation and Mitigation Strategy (REMS), which could delay the regulatory approval process. During an earnings call on May 6, 2025, it was disclosed that the company had conducted multiple meetings with the FDA concerning safety monitoring but ultimately decided to submit the NDA without the REMS. This oversight raises concerns regarding the company's decision-making and level of responsibility towards investors.

When the reality of these failures came to light, it resulted in the stock being traded at artificially inflated prices. Consequently, shareholders suffered considerable financial losses as the truth impacted the stock value.

Next Steps for Investors

The time for action is limited, with the lead plaintiff registration deadline looming on November 17, 2025. Interested shareholders should not hesitate to register for the class action—or to simply understand their rights in relation to this case. Once registered, investors will gain access to a portfolio monitoring service that will keep them informed on the case's progress.

The Gross Law Firm, recognized nationally for its class action initiatives, emphasizes its commitment to safeguarding the rights of investors who have suffered due to misleading business practices. Legal representation is advocating for justice on behalf of those affected, reinforcing the importance of corporate transparency and adhering to ethical business standards.

How to Contact The Gross Law Firm

For registration and more detailed information, investors are encouraged to visit the following link:
Investor Registration

For further inquiries, contact The Gross Law Firm directly:

• - Address: 15 West 38th Street, 12th Floor, New York, NY 10018
• - Email: [email protected]
• - Phone: (646) 453-8903

This is an imperative reminder for Cytokinetics investors to act swiftly and safeguard their rights. With the deadline fast approaching, proactive engagement could pave the way for a pathway towards recovery.